Saturday, 3 October 2026European Markets

Euro Climbs 14% Against Dollar as US Currency Hits Three-Year Low

The euro surged 14% against the dollar in 2025 as the US currency fell to its lowest levels since 2022. The British pound gained 7% to $1.31 despite UK market pressures. Currency volatility reflects monetary policy uncertainty ahead of the Federal Reserve leadership transition in June 2026.

Euro Climbs 14% Against Dollar as US Currency Hits Three-Year Low
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

The euro gained 14% against the dollar in 2025, reaching its strongest position in three years as the US currency weakened across all major pairs. The dollar fell to levels not seen since 2022 amid geopolitical uncertainty and questions over Federal Reserve policy direction.

The British pound rose 7% through 2025 but traded at $1.3086 on Tuesday, down 0.5% and facing analyst warnings of a potential drop below $1.30. Jordan Rochester at Mizuho Bank said the pound could breach that threshold as UK gilt yields climbed to 5.21% for 30-year bonds, the highest since 1998.

European exporters face pressure as the stronger euro makes goods less competitive in dollar markets. Simon Phillips, managing director at No1 Currency, said the pound remains "under pressure" despite year-to-date gains. The euro's surge creates challenges for EU manufacturers selling to US markets while benefiting European companies with dollar-denominated costs.

Currency markets are pricing in uncertainty around the Fed leadership transition scheduled for June 2026. The dollar's weakness coincides with ongoing Iran-US nuclear negotiations affecting commodity pricing and global trade flows.

Cross-border investment patterns are shifting as European assets become more expensive for dollar-based investors. UK markets showed mixed signals with the FTSE 100 closing at a record 9,911 points while the pound weakened against both the euro and dollar.

The currency realignment affects European corporate earnings, particularly for export-heavy sectors. A stronger euro reduces dollar-denominated revenue when converted back to euros, compressing margins for companies with significant US exposure.

European equity markets rose despite currency headwinds, with the Stoxx 600 hitting a record 583.4 points. France's CAC 40 gained 0.7% and Germany's DAX climbed 0.9%. Gold prices surged above $4,100 per ounce as investors sought alternatives to dollar assets.

The pound fell 0.4% to €1.13 against the euro, its lowest level since April 2023. UK Chancellor Rachel Reeves faces a Budget announcement on November 26 amid fiscal pressures and rising borrowing costs.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score3 source documents3 with a live linkVerifiability: Strong
  1. [1]News articleUk· November 12, 2025
    Pound hits two-year low against euro as Starmer under fire
  2. [2]News articleYahoo Finance· December 31, 2025
    Stock market today: Dow, S&P 500, Nasdaq post double-digit gains in 2025 as AI trade powers market once again
  3. [3]News articleYahoo Finance· February 17, 2026
    Stock market today: Dow, S&P 500, Nasdaq waver in volatile trading as AI anxiety lingers

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com